Liquidia surges after United Therapeutics request for preliminary injunction denied

June 14, 2024

in Stocks

Reading Time: 2 mins read

Update 6:20pm: Adds new United Therapeutics lawsuit against Liquidia.

Liquidia (NASDAQ:LQDA) jumped 12% in after hours trading after a judge denied United Therapeutics request for a preliminary injunction over lung-disease drug Yutrepia.

Support authors and subscribe to content

This is premium stuff. Subscribe to read the entire article.

Gain access to all our Premium contents.
More than 100+ articles.

Subscribe Now

Buy Article

Unlock this article and gain permanent access to read it.

Unlock Now

Liquidia surges after United Therapeutics request for preliminary injunction denied

Related Articles

Why David Einhorn Is Buying CNH, a Cheap Stock ‘No One Cares About’

5 Charts Showing the Immense Market Impact of Trump’s Presidential Win: BofA

Oil Outlook: US Production Boom, Weak China Demand to Lead to Oversupply in 2025

Stock Market Today: Tech Leads Sell-Off As Rate-Cut Odds Fall on Powell

Inflation Outlook: 4 Signs of Re-Inflation Investors Should Watch Out for

Oppenheimer Predicts up to 740% Rally for These 2 ‘Strong Buy’ Stocks

8 Tax Loopholes to Reduce or Avoid Capital Gains Taxes

5 Signs Economy Is Heading Toward Recession — Putting Stocks at Risk

It’s a Tough Time to Be a Tech Graduate

Navigate Site

Welcome Back!

Retrieve your password

Are you sure want to unlock this post?

Are you sure want to cancel subscription?

Liquidia surges after United Therapeutics request for preliminary injunction denied

Support authors and subscribe to content

Subscribe

Buy Article

Related Articles

Navigate Site

Follow Us

Welcome Back!

Retrieve your password

Are you sure want to unlock this post?

Are you sure want to cancel subscription?